Singapore — Chongqing Yunnao Medical Technology Co., Ltd (“Yunnao”), a leader in China’s BCI medical industrialization, and Neeuro Pte. Ltd. (“Neeuro”), a global digital therapeutics and brain fitness pioneer based in Singapore, have officially signed a Strategic Memorandum of Understanding (MOU) on 9 March 2026. This marks a landmark cross-border collaboration to advance BCI technology for children’s cognitive enhancement and mental wellness.
The partnership brings together two powerhouses in the neurotechnology field. Yunnao, a key incubated enterprise of the Chongqing Brain and Intelligent Science Center, holds a leading position in domestic BCI medical industrialization and developed Chongqing's first Class II Medical Device-approved BCI interactive robot. Neeuro brings its internationally recognized, wireless BCI technology and cognitive training solutions, which are backed by clinically validated research from Singapore’s Agency for Science, Technology and Research (A*STAR).
BCI is one of China's core future strategic industries with expected widespread adoption in the coming years. The two parties will focus on products localization, focusing on children's cognitive development.
Zhang Zheyi, General Manager of Chongqing Yunnao stated: "Our strategic collaboration with Neeuro underscores a steadfast commitment to the cognitive health and development of children, who represent the future of our nation. Addressing the significant societal and familial burdens posed by attention deficits and cognitive impairments, this partnership leverages Neeuro’s cutting edge wireless portable BCI technology and solutions clinically validated by A*STAR. Through our joint development, we aim to accelerate the delivery of precise, scientifically backed, and engaging solutions to millions of children across China."
Dr. Alvin Chan, CEO of Neeuro, added: "Localization is the cornerstone of our China strategy. Partnering with Yunnao, an organization at the heart of Chongqing’s brain science innovation, allows us to adapt our BCI technology to serve the Chinese market."
Both parties will move swiftly into a phased collaboration encompassing product localisation, regulatory navigation, and co-developed clinical programmes tailored to China's cognitive health needs. Underpinned by Neeuro's decade of clinical research and Yunnao's deep-rooted expertise in China's BCI medical landscape, this partnership is poised to redefine how BCI technology is delivered at scale — transforming it from a frontier innovation into an accessible, everyday therapeutic solution for children and families across China.
Yunnao is a high-tech enterprise incubated by the Chongqing Brain and Intelligent Science Center. With a solid R&D foundation in brain-related research, the company has been deeply involved in the BCI field for 10 years with strong capabilities in industrial implementation. Yunnao specializes in BCI rehabilitation robots, wearable smart devices, and AI-based precision diagnosis.
Neeuro is a global company that specialises in utilising Brain-Computer Interface technology to maximise the potential of users’ neurological agility and fitness. Since its inception in 2013, Neeuro’s extensive portfolio and an array of digital therapeutic and brain fitness solutions are backed by a decade of clinically validated research by A*STAR and other leading Singapore medical institutions. Neeuro’s holistic offerings reveal numerous potential avenues to explore complementary mental health options for children and adults facing various neurological challenges.